Zymeworks(US:ZYME) Seeking Alpha·2026-03-04 15:45分组1 - Zymeworks Inc. reported a weak 4Q25 earnings print with GAAP EPS at -$0.55, missing consensus expectations by approximately $0.21 [1] - Revenue for Zymeworks was reported at just $2.52 million, significantly missing estimates [1] 分组2 - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The focus is on identifying promising biotechnology companies that innovate through unique mechanisms, first-in-class therapies, or platform technologies [1] - The approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals [1]